Stoke Therapeutics (STOK) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.93
- Estimate
- -$0.78
- Surprise
- -19.1%
- Revenue (period 2026-06-30)
- $9.3M
- Score today
- 5.0/10
Revenue source: xbrl.
How the report landed
Stoke Therapeutics (STOK) reported a wider loss than forecast — adjusted EPS of -$0.93 against the -$0.78 estimate (a 19.1% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates STOK Sell at 5.0/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -19.1% surprise compares with a -16.5% four-quarter average. Next scheduled report: 2027-03-15.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Concentration risk — Pipeline: zorevunersen (STK-001)
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3)
- Consecutive earnings misses (3)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $26.99
- Price target
- $40.35
- Stop
- $25.10
- Upside to target
- +49.5%
- Reward-to-risk
- 3.3:1
Risk check: RSI 73 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
STOK at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.72B
- P/E (fwd)
- -7.0
- 52-week range
- $20.32–$40.22
- Off 52-week high
- 32.9%
- RSI (14)
- 73
- Volume vs avg
- 1.33×
- Score today
- 5.0/10